Introduced January 13, 2026
SB77
Log in to followAN ACT relating to ibogaine research in the Commonwealth.
Create new sections of KRS Chapter 218A to define terms; establish the ibogaine research and intellectual property fund to be administered by the Department of Agriculture for the purpose of allowing the department to enter a public-private partnership with a drug developer to conduct a clinical drug development trial or trials related to the use of ibogaine for the treatment of opioid use disorder, co-occurring substance use disorder, or any other neurological or mental health…
In effect since April 14, 2026
This act carries an emergency clause, so it took effect as soon as it became law instead of waiting the usual 90 days after the session adjourned (Ky. Constitution § 55).
Plain-language summary
This bill sets up a state fund to support clinical research trials on ibogaine, a substance being studied as a potential treatment for opioid use disorder and other mental health or neurological conditions. It allows the Department of Agriculture to partner with a private drug developer to conduct that research. The bill directs $21 million from the existing opioid abatement trust fund to support this effort over two fiscal years. Who it may affect: Kentuckians living with opioid use disorder or other substance use and mental health conditions, as well as researchers and drug developers working in this field.
Open official bill text (PDF)·Report a problem with the summary
Legislative History
Primary Sponsor
Donald Douglas
Senator · Senate District 22
Co-sponsors (6)
Danny Carroll
Senator · Senate District 02
Shelley Frommeyer
Senator · Senate District 24
Scott Madon
Senator · Senate District 29
Steve Rawlings
Senator · Senate District 11
Aaron Reed
Senator · Senate District 07
Lindsey Tichenor
Senator · Senate District 06
Something wrong on this page? Tell us